Skip to content

Nuvalent, Inc. NUVL Accretion (Amortization) of Discounts and Premiums, Investments

Accretion (Amortization) of Discounts and Premiums, Investments at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$1.53M+2,835%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$4.22M+42.2%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s accretion (amortization) of discounts and premiums, investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s accretion (amortization) of discounts and premiums, investments?
Nuvalent, Inc. (NUVL) reported accretion (amortization) of discounts and premiums, investments of $1.83M in Q1 2026.
How has Nuvalent, Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
Nuvalent, Inc.'s accretion (amortization) of discounts and premiums, investments decreased by 57.3% year-over-year, from $4.28M to $1.83M.
What does accretion (amortization) of discounts and premiums, investments mean?
This metric reflects the non-cash adjustments made to the carrying value of investment securities held by the company. It accounts for the gradual recognition of discounts or premiums on debt instruments over their holding period, impacting the reported cash flow from operations.